Publications - Invivoscribe

FEATURED PUBLICATIONS

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

admin2019-09-24T18:21:23+00:00March 21st, 2019|

VIEW PUBLICATION ⟶

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

admin2019-05-22T16:46:57+00:00August 25th, 2018|

VIEW PUBLICATION ⟶

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

admin2019-05-22T16:43:11+00:00August 22nd, 2018|

VIEW PUBLICATION ⟶

Targeted Deep Sequencing Reveals Clinically Relevant Subclonal IgHV Rearrangements in Chronic Lymphocytic Leukemia

admin2019-05-22T16:40:57+00:00May 2nd, 2017|

VIEW PUBLICATION ⟶

LATEST PUBLICATIONS

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

admin2019-09-24T18:21:23+00:00March 21st, 2019|

VIEW PUBLICATION ⟶

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

admin2019-05-22T16:46:57+00:00August 25th, 2018|

VIEW PUBLICATION ⟶

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

admin2019-05-22T16:43:11+00:00August 22nd, 2018|

VIEW PUBLICATION ⟶

Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

admin2019-04-29T19:01:48+00:00August 9th, 2017|

VIEW PUBLICATION ⟶

T and B cell clonal expansion in Ras associated lymphoproliferative disease (RALD) as revealed by next generation sequencing

admin2019-04-29T19:02:20+00:00May 30th, 2017|

VIEW PUBLICATION ⟶

Load More Posts

POSTERS

2019

AMP

Validation of an NGS based assay for monitoring FLT3 ITD and TKD variants in AML subjects
DOWNLOAD ⟶

Comparing Minimal Residual Disease Detection in Multiple Myeloma using NGS-Based LymphoTrack^® Assays and Flow Cytometry
DOWNLOAD ⟶

LymphoTrack® Low Positive Control and LymphoQuant^® Internal Control for MiSeq^® and Ion S5/PGM^™ LymphoTrack Assays
DOWNLOAD ⟶

Error Rate Normalization to Establish Position-Specific LoB & LoD in Next Generation Sequencing Assays
DOWNLOAD ⟶

2018

AMP

Minimal Residual Disease in AML can be Monitored Utilizing Cell-Free DNA
DOWNLOAD ⟶

Detection of Clonal Rearrangements in Multiple Myeloma Samples using LymphoTrack^® Assays
DOWNLOAD ⟶

Performance Evaluation of LymphoTrack^® Clonality Assays on Ion PGM<sup™ and Ion S5<sup™ Platforms
DOWNLOAD ⟶

EHA

Comparison of LymphoTrack^® Assays – MiSeq^® and Flow Cytometry for Clonality and Minimum Residual Disease Assessment in Multiple Myeloma
DOWNLOAD ⟶

Cell-Free DNA Monitoring of Minimal Residual Disease in AML using a Targeted NGS Gene Panel
DOWNLOAD ⟶

2017

AMP

Small Customizable Next-Genera5on Sequencing Based Target-Capture Panels in a Clinical Environment Can Detect Variant Muta5ons at Frequencies as Low as 0.5%
DOWNLOAD ⟶

Small Detec3ng B-Cell Clonality in Clinical Samples using a Comprehensive NGS LymphoTrack Dx^® IGH FR1/2/3 Assay
DOWNLOAD ⟶

Assessment of Minimal Residual Disease in Pa3ents with Acute Myeloid Leukemia by Monitoring FLT3 and NPM1 Mutations
DOWNLOAD ⟶

Genetic Heterogeneity and Stratification of AML Samples with NPM1 Mutation Detected by the MyAML^® NGS Test
DOWNLOAD ⟶

Clonality Detection Using Next-Generation Sequencing and Capillary Electrophoresis Methods in Suspect Lymphoproliferative Samples
DOWNLOAD ⟶

Validation of the LeukoStrat^® CDx FLT3 Mutation Assay: Used to Detect both Internal Tandem Duplication (ITD) and Tyrosine Kinase Domain (TKD) Mutations and Response to Midostaurin in 1058 Patients with AML
DOWNLOAD ⟶

Multiple Highly Concordant Assays Facilitate Analyses of Clinical Samples at Different Scales and Sensitivities
DOWNLOAD ⟶

Detection of Clonal TRG and TRB Gene Rearrangements Using Next-Generation Sequencing
DOWNLOAD ⟶

Analysis and Characterization of Hematologic Cancers using a Comprehensive NGS Panel Comprised of DNA and RNA Baits Targeting 704 Genes
DOWNLOAD ⟶

EHA

Small Customizable NGS Based Target Capture Panels Detect Variants in Clinical Specimens at Frequencies as Low as 0.5%
DOWNLOAD ⟶

Use of a Small Targeted Next-Generation Sequencing Panel for Monitoring Minimal Residual Disease in Acute Myeloid Leukemia
DOWNLOAD ⟶

Using Next-Generation Sequencing to Detect Clonal TRG and TRB Gene Rearrangements
DOWNLOAD ⟶

Detection of Clonality in Clinical Specimens from Suspected B-cell Malignancies using ComprehensiveIGH (FR1/2/3) LymphoTrack^® MiSeq^® and PGM^® Assays
DOWNLOAD ⟶

Analysis and Characterization of Hematologic Cancers using a Comprehensive NGS Panel Comprised of DNA and RNA Baits Targeting 704 GenesIGH (FR1/2/3) LymphoTrack^® MiSeq^® and PGM^® Assays
DOWNLOAD ⟶

2016

AMP

Minimal Residual Disease Detection of Lymphoid and Plasma Cell Neoplasms Using a Next-Generation Sequencing (NGS)-Based Assay
DOWNLOAD ⟶

Detec1on of Clonal Immunoglobulin and T-cell Receptor Gene Rearrangements in Acute Myeloid Leukemia
DOWNLOAD ⟶

LOD and Sensi;vity of MyHEME: A Comprehensive Targeted Sequencing Strategy
DOWNLOAD ⟶

Next-Generation Sequencing of FLT3/ITD for Minimal Residual Disease Monitoring in
Leukemia Patients
DOWNLOAD ⟶

Next-Generation Sequencing of NPM1 for Minimal Residual Disease Monitoring in Leukemia Patients
DOWNLOAD ⟶

Development of a Comprehensive IGH NGS Assay for DetecQng Suspected B-Cell Clonality
DOWNLOAD ⟶

A Single Institution Experience Using Next Generation Sequencing (NGS) for Analysis of Immunoglobulin Heavy Chain Variable Region (IGVH) Somatic Hypermutation in Chronic Lymphocytic Leukemia
DOWNLOAD ⟶

Next Generation Sequencing Demonstrates Clinical Utility and Increased Sensitivity in Detection of IgVH Somatic Hypermutation in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
DOWNLOAD ⟶

Assessment of Immunoglobulin Heavy Variable Gene Usage and Somatic Hypermutation Status in Splenic Marginal Zone Lymphomas Using Next Generation Sequencing
DOWNLOAD ⟶

2015

AMP

Development of LymphoTrack® Bioinformatics Methods: Clonality Testing, Somatic Hypermutation and Minimal Residual Disease
DOWNLOAD ⟶

Validation and clinical implementation of next generation sequencing for routine IGH and TCRG clonality assessment
DOWNLOAD ⟶

Next-Generation Sequencing for Detection of Clonal TRG Gene Rearrangements Shows Improved Specificity and Positive Predictive Value Compared to Fragment Analysis Using BIOMED-2 Primers and Capillary Electrophoresis
DOWNLOAD ⟶

EHA

Clinical Assessment of Chronic Lymphocytic Leukemia (CLL) Samples for Somatic Hypermutation Status by Next-Generation Sequencing and Sanger Sequencing
DOWNLOAD ⟶

Development of an NGS Assay for IGK that can be combined with IGH for Identifying Clonal Populations in Lymphoid Malignancies
DOWNLOAD ⟶

FEATURED PUBLICATIONS

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

admin2019-09-24T18:21:23+00:00March 21st, 2019|

VIEW PUBLICATION ⟶

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

admin2019-05-22T16:46:57+00:00August 25th, 2018|

VIEW PUBLICATION ⟶

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

admin2019-05-22T16:43:11+00:00August 22nd, 2018|

VIEW PUBLICATION ⟶

Targeted Deep Sequencing Reveals Clinically Relevant Subclonal IgHV Rearrangements in Chronic Lymphocytic Leukemia

admin2019-05-22T16:40:57+00:00May 2nd, 2017|

VIEW PUBLICATION ⟶

LATEST PUBLICATIONS

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

admin2019-09-24T18:21:23+00:00March 21st, 2019|

VIEW PUBLICATION ⟶

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

admin2019-05-22T16:46:57+00:00August 25th, 2018|

VIEW PUBLICATION ⟶

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

admin2019-05-22T16:43:11+00:00August 22nd, 2018|

VIEW PUBLICATION ⟶

Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

admin2019-04-29T19:01:48+00:00August 9th, 2017|

VIEW PUBLICATION ⟶

T and B cell clonal expansion in Ras associated lymphoproliferative disease (RALD) as revealed by next generation sequencing

admin2019-04-29T19:02:20+00:00May 30th, 2017|

VIEW PUBLICATION ⟶

Load More Posts

POSTERS

2019

AMP

Validation of an NGS based assay for monitoring FLT3 ITD and TKD variants in AML subjects
DOWNLOAD ⟶

Comparing Minimal Residual Disease Detection in Multiple Myeloma using NGS-Based LymphoTrack^® Assays and Flow Cytometry
DOWNLOAD ⟶

LymphoTrack® Low Positive Control and LymphoQuant^® Internal Control for MiSeq^® and Ion S5/PGM^™ LymphoTrack Assays
DOWNLOAD ⟶

Error Rate Normalization to Establish Position-Specific LoB & LoD in Next Generation Sequencing Assays
DOWNLOAD ⟶

2018

AMP

Minimal Residual Disease in AML can be Monitored Utilizing Cell-Free DNA
DOWNLOAD ⟶

Detection of Clonal Rearrangements in Multiple Myeloma Samples using LymphoTrack^® Assays
DOWNLOAD ⟶

Performance Evaluation of LymphoTrack^® Clonality Assays on Ion PGM<sup™ and Ion S5<sup™ Platforms
DOWNLOAD ⟶

EHA

Comparison of LymphoTrack^® Assays – MiSeq^® and Flow Cytometry for Clonality and Minimum Residual Disease Assessment in Multiple Myeloma
DOWNLOAD ⟶

Cell-Free DNA Monitoring of Minimal Residual Disease in AML using a Targeted NGS Gene Panel
DOWNLOAD ⟶

2017

AMP

Small Customizable Next-Genera5on Sequencing Based Target-Capture Panels in a Clinical Environment Can Detect Variant Muta5ons at Frequencies as Low as 0.5%
DOWNLOAD ⟶

Small Detec3ng B-Cell Clonality in Clinical Samples using a Comprehensive NGS LymphoTrack Dx^® IGH FR1/2/3 Assay
DOWNLOAD ⟶

Assessment of Minimal Residual Disease in Pa3ents with Acute Myeloid Leukemia by Monitoring FLT3 and NPM1 Mutations
DOWNLOAD ⟶

Genetic Heterogeneity and Stratification of AML Samples with NPM1 Mutation Detected by the MyAML^® NGS Test
DOWNLOAD ⟶

Clonality Detection Using Next-Generation Sequencing and Capillary Electrophoresis Methods in Suspect Lymphoproliferative Samples
DOWNLOAD ⟶

Validation of the LeukoStrat^® CDx FLT3 Mutation Assay: Used to Detect both Internal Tandem Duplication (ITD) and Tyrosine Kinase Domain (TKD) Mutations and Response to Midostaurin in 1058 Patients with AML
DOWNLOAD ⟶

Multiple Highly Concordant Assays Facilitate Analyses of Clinical Samples at Different Scales and Sensitivities
DOWNLOAD ⟶

Detection of Clonal TRG and TRB Gene Rearrangements Using Next-Generation Sequencing
DOWNLOAD ⟶

Analysis and Characterization of Hematologic Cancers using a Comprehensive NGS Panel Comprised of DNA and RNA Baits Targeting 704 Genes
DOWNLOAD ⟶

EHA

Small Customizable NGS Based Target Capture Panels Detect Variants in Clinical Specimens at Frequencies as Low as 0.5%
DOWNLOAD ⟶

Use of a Small Targeted Next-Generation Sequencing Panel for Monitoring Minimal Residual Disease in Acute Myeloid Leukemia
DOWNLOAD ⟶

Using Next-Generation Sequencing to Detect Clonal TRG and TRB Gene Rearrangements
DOWNLOAD ⟶

Detection of Clonality in Clinical Specimens from Suspected B-cell Malignancies using ComprehensiveIGH (FR1/2/3) LymphoTrack^® MiSeq^® and PGM^® Assays
DOWNLOAD ⟶

Analysis and Characterization of Hematologic Cancers using a Comprehensive NGS Panel Comprised of DNA and RNA Baits Targeting 704 GenesIGH (FR1/2/3) LymphoTrack^® MiSeq^® and PGM^® Assays
DOWNLOAD ⟶

2016

AMP

Minimal Residual Disease Detection of Lymphoid and Plasma Cell Neoplasms Using a Next-Generation Sequencing (NGS)-Based Assay
DOWNLOAD ⟶

Detec1on of Clonal Immunoglobulin and T-cell Receptor Gene Rearrangements in Acute Myeloid Leukemia
DOWNLOAD ⟶

LOD and Sensi;vity of MyHEME: A Comprehensive Targeted Sequencing Strategy
DOWNLOAD ⟶

Next-Generation Sequencing of FLT3/ITD for Minimal Residual Disease Monitoring in
Leukemia Patients
DOWNLOAD ⟶

Next-Generation Sequencing of NPM1 for Minimal Residual Disease Monitoring in Leukemia Patients
DOWNLOAD ⟶

Development of a Comprehensive IGH NGS Assay for DetecQng Suspected B-Cell Clonality
DOWNLOAD ⟶

A Single Institution Experience Using Next Generation Sequencing (NGS) for Analysis of Immunoglobulin Heavy Chain Variable Region (IGVH) Somatic Hypermutation in Chronic Lymphocytic Leukemia
DOWNLOAD ⟶

Next Generation Sequencing Demonstrates Clinical Utility and Increased Sensitivity in Detection of IgVH Somatic Hypermutation in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
DOWNLOAD ⟶

Assessment of Immunoglobulin Heavy Variable Gene Usage and Somatic Hypermutation Status in Splenic Marginal Zone Lymphomas Using Next Generation Sequencing
DOWNLOAD ⟶

2015

AMP

Development of LymphoTrack® Bioinformatics Methods: Clonality Testing, Somatic Hypermutation and Minimal Residual Disease
DOWNLOAD ⟶

Validation and clinical implementation of next generation sequencing for routine IGH and TCRG clonality assessment
DOWNLOAD ⟶

Next-Generation Sequencing for Detection of Clonal TRG Gene Rearrangements Shows Improved Specificity and Positive Predictive Value Compared to Fragment Analysis Using BIOMED-2 Primers and Capillary Electrophoresis
DOWNLOAD ⟶

EHA

Clinical Assessment of Chronic Lymphocytic Leukemia (CLL) Samples for Somatic Hypermutation Status by Next-Generation Sequencing and Sanger Sequencing
DOWNLOAD ⟶

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Browse our comprehensive menu of product & testing services.

A proven strategy to acceleratedrug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

March 21st, 2019 Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

August 25th, 2018 A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

August 22nd, 2018 Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

FEATURED PUBLICATIONS

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

Targeted Deep Sequencing Reveals Clinically Relevant Subclonal IgHV Rearrangements in Chronic Lymphocytic Leukemia

LATEST PUBLICATIONS

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

T and B cell clonal expansion in Ras associated lymphoproliferative disease (RALD) as revealed by next generation sequencing

POSTERS

2019

AMP

2018

AMP

EHA

2017

AMP

EHA

2016

AMP

2015

AMP

EHA

FEATURED PUBLICATIONS

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

Targeted Deep Sequencing Reveals Clinically Relevant Subclonal IgHV Rearrangements in Chronic Lymphocytic Leukemia

LATEST PUBLICATIONS

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

T and B cell clonal expansion in Ras associated lymphoproliferative disease (RALD) as revealed by next generation sequencing

POSTERS

2019

AMP

2018

AMP

EHA

2017

AMP

EHA

2016

AMP

2015

AMP

EHA

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

A proven strategy to accelerate
drug approvals

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

March 21st, 2019
Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

August 25th, 2018
A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

August 22nd, 2018
Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL